Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsNVST -4.37%79 EV-to-OCF is 16.40 as of Aug. 07, 2026, which is 8% below its 10-year median of 17.84. GuruFocus rates NVST with a GF Score™ of 79/100 and a GF Value™ of $24.21 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Envista Holdings ranks worse than 68.9% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Envista Holdings's Enterprise Value is $4,962 Mil.
Envista Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $303 Mil. Therefore, Envista Holdings's EV-to-OCF for today is 16.40.
The historical rank and industry rank for Envista Holdings's EV-to-OCF or its related term are showing as below:
NVST'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.13 Med: 17.84 Max: 44.99
Current: 16.4
During the past 10 years, the highest EV-to-OCF of Envista Holdings was 44.99. The lowest was 8.13. And the median was 17.84.
NVST's EV-to-OCF is ranked worse than 68.9% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.835
vs NVST: 16.40
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Envista Holdings's PE Ratio (TTM) for today is calculated as:
Envista Holdings's share price for today is $27.38.
Envista Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Envista Holdings EV-to-OCF Related Terms
Envista Holdings EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Envista Holdings's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Envista Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Envista Holdings's EV-to-OCF falls into.
Envista Holdings's current Enterprise Value is $4,962 Mil.
Envista Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $303 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envista Holdings (NVST) has a EV-to-OCF of 16.40 as of Aug. 07, 2026. This is near median its historical median of 17.84. Over the past decade, Envista Holdings' EV-to-OCF has ranged from 8.13 to 44.99. According to the industry distribution chart, Envista Holdings ranks #587 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 68.9%.
Is Envista Holdings' EV-to-OCF too high?
Envista Holdings' current EV-to-OCF of 16.40 is near median its 10-year median of 17.84. Over the past 10 years, this metric has ranged from a low of 8.13 to a high of 44.99. The Medical Devices & Instruments industry median EV-to-OCF is 7.84. Envista Holdings' value of 16.40 is 109.3% above this industry median. Based on the distribution chart, Envista Holdings ranks #587 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Envista Holdings has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' EV-to-OCF compare to MMSI and ICUI?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #587 out of 852 companies for EV-to-OCF. This places Envista Holdings in the lower half of its industry. The industry median EV-to-OCF is 7.84. Envista Holdings' value of 16.40 is 109.3% above this benchmark. Historically, Envista Holdings' own EV-to-OCF has ranged from 8.13 to 44.99 over the past decade. While the company's 10-year median is 17.84 vs. the industry median of 7.84, Envista Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.84, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current EV-to-OCF of 16.40 is 109.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current EV-to-OCF is 16.40, which is near median its own 10-year median of 17.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Based on GuruFocus' analysis, Envista Holdings (NVST) is currently considered Modestly Overvalued. The stock's GF Value™ is $24.21, compared to a current price of $27.38 — trading 13.1% above its estimated fair value. The current EV-to-OCF is 16.40, which is near median its 10-year median of 17.84 and 109.3% above the Medical Devices & Instruments industry median of 7.84. Envista Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Envista Holdings (NVST), the current EV-to-OCF is 16.40 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of $27.38 is trading 13.1% above its estimated GF Value™ of $24.21.
GuruFocus considers Envista Holdings to be Modestly Overvalued.
Key valuation signals for NVST:
EV-to-OCF: 16.40 (near median its 10-year median of 17.84)
GF Value™: $24.21 vs. price of $27.38 (13.1% above fair value)
Industry Position: 109.3% above the Medical Devices & Instruments median (#587 of 852)
No single metric tells the full story. See the NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
79GF Score
Get the complete analysis for NVST
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVST has been successfully added to your 
